Alpha Cognition Inc. Common Stock (ACOG)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Alpha Cognition Inc. Common Stock
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.7M | 2.8M | 2.8M | 3.5M |
| Gross Profit | 1.1M | 2.2M | 2.5M | 3.3M |
| Operating Income | -5.7M | -5.3M | -7.9M | -8.1M |
| Net Income | -10.5M | -1.3M | -6.9M | -6.5M |
| Diluted EPS | $-0.65 | $-0.30 | $nan | $-0.32 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 10.2M |
| Gross Profit | 0.00 | 8.3M | ||
| Operating Income | -13.5M | -9.6M | -11.5M | -22.6M |
| Net Income | -12.1M | -13.8M | -14.8M | -20.7M |
| Diluted EPS | $-4.50 | $-3.84 | $-2.04 | $-1.18 |